February 18, 2025
Schizophrenia
Listening to the call and reviewing the earnings released by Medtronic this morning we’re beginning to wonder whether when it comes to their struggling diabetes franchise if schizophrenia has set it. The company continues to hype their Simplera sensor while also touting their relationship with Abbott. On the diabetes slide it states:
“Advanced CGM portfolio refresh with Abbott partnership on track for US FDA submission in 2HCY25; Simplera Sync sensor pending FDA approval”
As we have been reporting this “partnership” with Abbott while necessary isn’t going all that well. It will be interesting if they actually . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
